drugset
drugset / Trial / NCT05550246

Identifying Sleep Apnea Patients That Best Respond to Atomoxetine Plus Oxybutynin Therapy

NCT05550246 ↗

Phase 1/2 Unknown 22 enrolled Brigham and Women's Hospital
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Atomoxetine-plus-oxybutynin therapy (AtoOxy) has been shown to substantially reduce obstructive sleep apnea severity (OSA) in about half of patients. Here, the investigators will study which patients respond meaningfully to therapy using pathophysiological traits measured at baseline sleep studies.

Timeline

Start
2022-05-05
Primary completion
2024-12
Completion
2024-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Atomoxetine Other / unclassified 80 mg —
Subject Oxybutynin Small molecule 5 mg —

Indications

obstructive sleep apnea syndrome